BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026
BioLineRx and Hemispherian presented preclinical data at ESMO 2026 showing GLIX1 synergizes with three PARP inhibitors (olaparib, veliparib, niraparib) in HR-proficient ovarian cancer models, with ZIP synergy scores of 10.9-43.2. In a patient-derived xenograft model, a low-dose GLIX1 plus olaparib combination produced statistically significant tumor growth inhibition comparable to cisplatin, outperforming either agent alone at optimal doses.
Key figures
- Drug Name
- GLIX1
- Phase Of Trial
- Phase 1/2a
- Glix1 low dose
- 50 mg/kg daily
- Olaparib low dose
- 10 mg/kg daily
- Zip synergy scores
- 10.9-43.2 across olaparib, veliparib, niraparib
- Tumor to plasma ratio
- approximately 50%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.